| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Parthenolide | CTRPv2 | pan-cancer | AAC | -0.0094 | 0.8 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0083 | 0.8 |
| mRNA | Sunitinib | CTRPv2 | pan-cancer | AAC | 0.0084 | 0.8 |
| mRNA | QL-XII-61 | GDSC1000 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | BRD-K02251932 | CTRPv2 | pan-cancer | AAC | 0.0092 | 0.8 |
| mRNA | BRD9876 | CTRPv2 | pan-cancer | AAC | 0.009 | 0.8 |
| mRNA | BRD-K11533227 | CTRPv2 | pan-cancer | AAC | -0.0088 | 0.8 |
| mRNA | BRD8958 | CTRPv2 | pan-cancer | AAC | 0.0092 | 0.8 |
| mRNA | SJ-172550 | CTRPv2 | pan-cancer | AAC | 0.009 | 0.8 |
| mRNA | Crizotinib | FIMM | pan-cancer | AAC | -0.047 | 0.8 |